Evidence map›Paper›PMID 39053018›Full record

ArticleTechnology in cancer research & treatment

VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer.

Xuechao Yang, Shu Zhang, Yang Yang, Xiaoqun Duan, Xiaochuan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuechao YangCollege of Biomedical Industry, Guilin Medical University, Guilin, Guangxi, China.ORCID 0009-0000-3437-1916
Shu ZhangSuzhou Xuhui Analysis Co., Ltd, Kunshan, Jiangsu, China.
Yang YangCollege of Pharmacy, Guilin Medical University, Guilin, Guangxi, China.
Xiaoqun DuanCollege of Biomedical Industry, Guilin Medical University, Guilin, Guangxi, China.
Xiaochuan LiCollege of Biomedical Industry, Guilin Medical University, Guilin, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ApoptosisCarcinoma, Non-Small-Cell LungCell MovementCell ProliferationLung NeoplasmsMutationProto-Oncogene Proteins p21(ras)Xenograft Model Antitumor AssaysAnimalsAntineoplastic AgentsCell Line, TumorDisease Models, AnimalHumansMAP Kinase Signaling SystemMiceAntineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)KRASG12Cnon-small cell lung cancersmall molecule inhibitortherapeutic interventionVT204

Identifiers

PMID39053018
PMCPMC11282536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.